… The JO25567 study was a randomised, multicentre, phase 2 trial that compared
bevacizumab–erlotinib with erlotinib alone as first-line treatments in 154 Japanese patients with …

… Japanese patients with NSCLC who received nivolumab were analyzed retrospectively.
Patients who had started nivolumab treatment between April 2016 and December 2016 were …

… patients with lung adenocarcinoma, this research revealed KRAS mutations in 4.3% of
Japanese patients … less frequent in Japanese patients than in Caucasian patients, even among …

… 13,951 patients with nonsquamous non-small cell lung cancer included in this study, 5780
patients (… in a large cohort of Japanese patients with surgically treated lung adenocarcinoma …

… -stage lung cancer is only indicated for selected patients with … 90s in Japan, the early detection
of small-sized early lung … is a highly malignant disease, according to our results, patients …

… frail patients from 21 Japanese institutions after meeting the inclusion criteria.
Chemotherapy-naive patients withEGFR-activating mutation–positive non–small cell lung cancer …

… The J-ALEX study compared the efficacy and safety of alectinib with crizotinib in Japanese
patients with advanced ALK-positive non-small-cell lung cancer (NSCLC). Superiority in …

… This study is the first prospective clinical trial in Japanese patients to evaluate brigatinib
efficacy and safety in patients with ALK-positive NSCLC who had not received ALK TKI treatment…

… Our Japan-specific trial may limit the generalizability of the results, since all enrolled
participants are Japanese patients with NSCLC who usually show better survival than Western …

… To select lung cancer that has no nodal involvement or lymphovascular invasion, the Japan
… The study defined radiologic noninvasive lung cancer as lung cancer 2 cm or less in size …